Table 1.

Prognostic factor in sarcoidosis according to clinical, radiographic and laboratory findings

Prognostic factor according to	Poor prognosis	Good prognosis
Gender	Female  More symptoms  Lower quality of life  More functional impairment  Higher incidence of coexisting autoimmune disorders  More hospitalization	Male  Ankle arthritis
Age	Elderly-onset	Younger-onset
Ethnicity	African-American  Extrapulmonary involvement  Progressive disease  High mortality rates	Caucasian  Erythema nodosum  Löfgren syndrome
Genetic	HLA-DQB1*1501 HLA-DQB1*0602 Annexin A11 gene	HLA-DQB1*0201 HLA-DRB1*0301 TNF-308A allele MEFV gene
Clinical phenotype	Chronic sarcoidosis	Acute sarcoidosis
Pulmonary involvement	Low PFT and DLCO  Bronchial obstruction  Pulmonary fibrosis  PH	Acute alveolitis Normal PFT Normal DLCO
Heart involvement	A-V block, ventricular tachycardia, myocarditis	Pericarditis
Neurosarcoidosis	epilepsy Intracranial mass Spinal cord Optic nerve involvement	Facial nerve palsy Aseptic meningitis Isolated headache Vertigo
Ocular involvement	Panuveitis	Anterior uveitis
Skin involvement	Lupus pernio Chronic skin lesion	Erythema nodosum Scar sarcoidosis
Musculoskeletal involvement	Chronic arthritis Jaccoud deformity Dactilytis Granulomatous myositis Cystic bone lesions	Acute arthritis Arthralgia
Radiographic	Stage 3 and Stage 4	Stage 1 and Stage 2
Laboratory	Neopterin, sIL-2R, KL-6, TNF-alpha, chitotriosidase, tryptase, chitotriosidase, hypercalcemia, hypercalciuria, Th17	Low TNF-alpha CRP

PFT: Pulmonary function tests, A-V: Atrioventricular, sIL-2R: Soluble interleukine-2 receptor, TNF: Tumor necrosis factor, KL-6: Krebs Von den Lungen-6, Th: T-helper; DLCO: Diffusion lung carbon monoxide, PH: Pulmonary hypertension, CRP: C-reactive protein